These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 22428052)

  • 21. Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma.
    Hanihara M; Miyake K; Watanabe A; Yamada Y; Oishi N; Kawataki T; Inukai T; Kondo T; Kinouchi H
    Clin Epigenetics; 2020 Nov; 12(1):174. PubMed ID: 33203454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.
    Kanemoto M; Shirahata M; Nakauma A; Nakanishi K; Taniguchi K; Kukita Y; Arakawa Y; Miyamoto S; Kato K
    BMC Cancer; 2014 Aug; 14():641. PubMed ID: 25175833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.
    van Nifterik KA; van den Berg J; van der Meide WF; Ameziane N; Wedekind LE; Steenbergen RD; Leenstra S; Lafleur MV; Slotman BJ; Stalpers LJ; Sminia P
    Br J Cancer; 2010 Jun; 103(1):29-35. PubMed ID: 20517307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
    Melguizo C; Prados J; González B; Ortiz R; Concha A; Alvarez PJ; Madeddu R; Perazzoli G; Oliver JA; López R; Rodríguez-Serrano F; Aránega A
    J Transl Med; 2012 Dec; 10():250. PubMed ID: 23245659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
    Thon N; Thorsteinsdottir J; Eigenbrod S; Schüller U; Lutz J; Kreth S; Belka C; Tonn JC; Niyazi M; Kreth FW
    J Neurol; 2017 Feb; 264(2):350-358. PubMed ID: 27921166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods.
    Karayan-Tapon L; Quillien V; Guilhot J; Wager M; Fromont G; Saikali S; Etcheverry A; Hamlat A; Loussouarn D; Campion L; Campone M; Vallette FM; Gratas-Rabbia-Ré C
    J Neurooncol; 2010 May; 97(3):311-22. PubMed ID: 19841865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
    Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
    J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
    Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
    Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM.
    Shah N; Lin B; Sibenaller Z; Ryken T; Lee H; Yoon JG; Rostad S; Foltz G
    PLoS One; 2011 Jan; 6(1):e16146. PubMed ID: 21249131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
    Wang L; Li Z; Liu C; Chen L; Liu L; Hu Z; Zhao L; Lu D; Teng L
    Pathol Res Pract; 2017 Dec; 213(12):1489-1493. PubMed ID: 29103769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.
    Quillien V; Lavenu A; Ducray F; Joly MO; Chinot O; Fina F; Sanson M; Carpentier C; Karayan-Tapon L; Rivet P; Entz-Werle N; Legrain M; Zalcman EL; Levallet G; Escande F; Ramirez C; Chiforeanu D; Vauleon E; Figarella-Branger D
    Oncotarget; 2016 Sep; 7(38):61916-61929. PubMed ID: 27542245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Impact of
    Jovanović N; Mitrović T; Cvetković VJ; Tošić S; Vitorović J; Stamenković S; Nikolov V; Kostić A; Vidović N; Krstić M; Jevtović-Stoimenov T; Pavlović D
    Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30717206
    [No Abstract]   [Full Text] [Related]  

  • 33. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
    Iliadis G; Kotoula V; Chatzisotiriou A; Televantou D; Eleftheraki AG; Lambaki S; Misailidou D; Selviaridis P; Fountzilas G
    BMC Cancer; 2012 Jan; 12():3. PubMed ID: 22214427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
    Rivera AL; Pelloski CE; Gilbert MR; Colman H; De La Cruz C; Sulman EP; Bekele BN; Aldape KD
    Neuro Oncol; 2010 Feb; 12(2):116-21. PubMed ID: 20150378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.
    Xie H; Tubbs R; Yang B
    Int J Clin Exp Pathol; 2015; 8(1):636-42. PubMed ID: 25755756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
    Håvik AB; Brandal P; Honne H; Dahlback HS; Scheie D; Hektoen M; Meling TR; Helseth E; Heim S; Lothe RA; Lind GE
    J Transl Med; 2012 Mar; 10():36. PubMed ID: 22390413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
    Parkinson JF; Wheeler HR; Clarkson A; McKenzie CA; Biggs MT; Little NS; Cook RJ; Messina M; Robinson BG; McDonald KL
    J Neurooncol; 2008 Mar; 87(1):71-8. PubMed ID: 18004504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.
    Etcheverry A; Aubry M; Idbaih A; Vauleon E; Marie Y; Menei P; Boniface R; Figarella-Branger D; Karayan-Tapon L; Quillien V; Sanson M; de Tayrac M; Delattre JY; Mosser J
    PLoS One; 2014; 9(9):e104455. PubMed ID: 25233099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients.
    Radke J; Koch A; Pritsch F; Schumann E; Misch M; Hempt C; Lenz K; Löbel F; Paschereit F; Heppner FL; Vajkoczy P; Koll R; Onken J
    Acta Neuropathol Commun; 2019 Jun; 7(1):89. PubMed ID: 31167648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.